Noninvasive Biomarkers of Liver Fibrosis: An Overview

Fallatah, Hind I

doi:10.1155/2014/357287

Cited by 68 publications

(78 citation statements)

References 158 publications

(275 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One common classification is a scale from 0 to 4. [30][31][32] The degree of fibrosis can be assessed as none, minimal, mild, moderate or severe. Ultrasonography is widely used in the diagnosis of liver fibrosis because it is an inexpensive and accurate method.…”

Section: Diagnosis Of Liver Fibrosismentioning

confidence: 99%

Nanoparticles for the treatment of liver fibrosis

Surendran¹,

Thomas²,

Moon³

et al. 2017

IJN

114

View full text Add to dashboard Cite

Chronic liver diseases represent a global health problem due to their high prevalence worldwide and the limited available curative treatment options. They can result from various causes, both infectious and noninfectious diseases. The application of nanoparticle (NP) systems has emerged as a rapidly evolving area of interest for the safe delivery of various drugs and nucleic acids for chronic liver diseases. This review presents the pathogenesis, diagnosis and the emerging nanoparticulate systems used in the treatment of chronic liver diseases caused by liver fibrosis. Activated hepatic stellate cell (HSC) is considered to be the main mechanism for liver fibrosis. Ultrasonography and magnetic resonance imaging techniques are widely used noninvasive diagnostic methods for hepatic fibrosis. A variety of nanoparticulate systems are mainly focused on targeting HSC in the treatment of hepatic fibrosis. As early liver fibrosis is reversible by current NP therapy, it is being studied in preclinical as well as clinical trials. Among various nanoparticulate systems, inorganic NPs, liposomes and nanomicelles have been widely studied due to their distinct properties to deliver drugs as well as other therapeutic moieties. Liposomal NPs in clinical trials is considered to be a milestone in the treatment of hepatic fibrosis. Currently, NP therapy for liver fibrosis is updating fast, and hopefully, it can be the future remedy for liver fibrosis.

show abstract

Section: Diagnosis Of Liver Fibrosismentioning

confidence: 99%

Nanoparticles for the treatment of liver fibrosis

Surendran¹,

Thomas²,

Moon³

et al. 2017

IJN

114

View full text Add to dashboard Cite

show abstract

“…Liver biopsy may be poorly tolerated by patients, especially if it must be repeated. Recently transjugular liver biopsy has been used, which is safer and better tolerated but is available only in specialized centers [5,8,9]. Therefore, in the last decade, particular attention is paid to serum biomarkers.…”

Section: Non-invasive Diagnostics Of Liver Fibrosismentioning

confidence: 99%

“…and procollagen IV (PCIV) [5,9,12,15]. These markers are an indicator for deposition of collagen fi bers in the extracellular matrix.…”

Section: Procollagens: Procollagen I Carboxy-terminal (Pcicp) Procolmentioning

confidence: 99%

“…It is synthesized by the liver stellate cells. It is the most validated marker that most accurately predicts advanced fi brosis in chronic Hepatitis C and B, steatosis and alcoholic liver disease [9,17,18]. Due to its high negative predictive value (98-100%) it may be used alone in clinical practice for the exclusion of advanced fi brosis.…”

Section: Hyaluronic Acid (Ha)mentioning

confidence: 99%

“…In patients with nonalcoholic fatty liver disease, HA is selected for best fi brosis marker with specifi city and sensitivity of 88-95% and 86-100%, respectively. HA is involved in several panels [6,8,9,16].…”

Section: Hyaluronic Acid (Ha)mentioning

confidence: 99%

See 2 more Smart Citations

Non-invasive Diagnostics of Liver Fibrosis

Mihaylov

Pencheva

Stoeva

et al. 2017

Acta Medica Bulgarica

View full text Add to dashboard Cite

show abstract

Type V Collagen in Health, Disease, and Fibrosis

Mak

Png

Lee

2016

The Anatomical Record

137

View full text Add to dashboard Cite

Type V collagen (COLV) is a regulatory fibril-forming collagen. It has at least three different molecular isoforms-a1(V) 2 a2(V), a1(V) 3, and a1(V)a2(V)a3(V)-formed by combinations of three different polypeptide a chains-a1(V), a2(V), and a3(V). COL V is a relatively minor collagen of the extracellular matrix (ECM). Morphologically, COLV occurs as heterotypic fibrils with type I collagen (COLI), microfilaments, or 12-nm-thick fibrils. COLV is synthesized in various mesenchymal cells and its gene expression is modulated by TGF-b and growth factors. While resistant to digestion by interstitial collagenases, native and denatured COLV are degraded by metalloproteinases and gelatinases, thereby promoting ECM remodeling. COLV interacts with matrix collagens and structural proteins, conferring structural integrity to tissue scaffolds. It binds matrix macromolecules, modulating cellular behavior, and functions. COLV coassembles with COLI into heterotypic fibrils in the cornea and skin dermis, acting as a dominant regulator of collagen fibrillogenesis. COLV deficiency is associated with loss of corneal transparency and classic EhlersDanlos syndrome, while COLV overexpression is found in cancer, granulation tissue, inflammation, atherosclerosis, and fibrosis of lungs, skin, kidneys, adipose tissue, and liver. COLV isoform containing the a3(V) chain is involved in mediating pancreatic islet cell functions. In the liver, COLV is a minor but regular component of the ECM. Increases in COLV are associated with both early and advanced hepatic fibrosis. The neoepitopes of COLV have been shown to be a useful noninvasive serum biomarker for assessing fibrotic progression and resolution in experimental hepatic fibrosis. COLV is multifunctional in health, disease, and fibrosis. Anat Rec, 299:613-629, 2016. V C 2016 Wiley Periodicals, Inc.Key words: collagen V synthesis and degradation; collagen V deficiency and overexpression; collagen V in disease and fibrosis; collagen V neoepitopes; hepatic fibrosis biomarker

show abstract

Noninvasive Biomarkers of Liver Fibrosis: An Overview

Cited by 68 publications

References 158 publications

Nanoparticles for the treatment of liver fibrosis

Nanoparticles for the treatment of liver fibrosis

Non-invasive Diagnostics of Liver Fibrosis

Type V Collagen in Health, Disease, and Fibrosis

Contact Info

Product

Resources

About